Benzimidazole Opioids - DEA

The document discusses benzimidazole-opioids, synthetic substances with opioid-like effects that are being trafficked and abused, leading to adverse health effects, including fatalities. These substances, which act as mu-opioid receptor agonists, are not approved for medical use in the U.S. and are classified as Schedule I controlled substances. Since 2019, their presence in toxicology cases and drug seizures has significantly increased, posing serious public health and safety risks. The DEA highlights their high potential for addiction, respiratory depression, and the dangers of unregulated distribution.

Click HERE to Download for FREE.